Recent developments highlight Inspire Medical Systems' Q3 earnings and revenues surpassing expectations, new CPT code approvals for hypoglossal nerve stimulation, and ongoing efforts to raise awareness and adoption of its therapy.

• Inspire Medical Systems reported Q3 earnings and revenues exceeding expectations, reflecting operational progress [N1].
• Key metrics from the Q3 earnings report indicate continued patient adoption and therapy utilization [N2].
• The company held a Q3 2026 earnings conference call to discuss financial results and business updates [N3].
• Inspire secured new CPT codes for hypoglossal nerve stimulation, enhancing reimbursement pathways [N5][N6].
• Q2 results showed a return to profitability and an upward revision of the full-year 2026 outlook [N8].

The company has demonstrated strong clinical validation with sustained patient outcomes and high compliance rates, which underpin its market adoption. Recent regulatory approvals for new CPT codes enhance reimbursement potential. The direct sales model combined with targeted marketing and patient engagement programs supports continued awareness and demand growth. The robust intellectual property portfolio and ongoing product innovation, including the Inspire V neurostimulator, provide a foundation for competitive differentiation and potential expansion into new markets or indications.

The company reported a net loss in the latest quarter, indicating ongoing profitability challenges. The market for OSA treatment is competitive, with CPAP remaining the standard despite compliance issues. Adoption depends on continued reimbursement coverage and physician acceptance. Regulatory or reimbursement changes could impact market access. The minimally invasive procedure requires physician training and patient willingness to undergo implantation, which may limit uptake. Clinical outcomes, while positive, require ongoing validation to sustain confidence among stakeholders.

Inspire Medical Systems benefits from a first-mover advantage as the first FDA-approved neurostimulation therapy for moderate to severe OSA, supported by a significant body of clinical evidence including long-term efficacy and safety data. The company's extensive intellectual property portfolio protects its technology and product innovations. Its dedicated sales force and market access teams facilitate adoption and reimbursement, while direct-to-consumer marketing enhances patient awareness. The combination of regulatory approvals, clinical validation, reimbursement coverage, and ongoing innovation creates barriers to entry for competitors and supports sustained market presence.

• Regulatory and Reimbursement Risk: Changes in regulatory approvals or reimbursement policies could affect market access and patient adoption of Inspire therapy.
• Market Adoption Risk: Physician and patient acceptance of the minimally invasive neurostimulation therapy versus established CPAP treatment may limit growth.
• Financial Performance Risk: The company reported net losses, indicating risks related to achieving sustained profitability.
• Competitive Risk: Emerging competitors or alternative therapies for OSA could impact Inspire's market share and pricing power.

• Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing minimally invasive solutions for patients with moderate to severe obstructive sleep apnea (OSA) [S1].
• The company's proprietary Inspire system is the first FDA, EU MDR, and Japan PMDA-approved neurostimulation technology for OSA treatment, delivering mild hypoglossal nerve stimulation to maintain an open airway [S1].
• Inspire therapy is indicated for patients with moderate to severe OSA who do not have significant central sleep apnea or complete concentric collapse of the airway at the soft palate level [S1].
• More than 125,000 patients have been treated with Inspire therapy across the U.S., Europe, and Asia [S1].
• OSA is a chronic disease characterized by airway blockages during sleep, leading to health risks such as hypertension, heart failure, and stroke if untreated [S1].
• CPAP is the leading therapy but has low patient compliance due to discomfort; Inspire therapy offers a minimally invasive alternative with high patient compliance and satisfaction [S1].
• Clinical data supporting Inspire therapy includes seven sponsored and over 100 independent studies with more than 385 peer-reviewed publications, demonstrating safety, efficacy, and long-term benefits up to five years [S1].
• The pivotal STAR trial showed approximately 70% reduction in median apnea-hypopnea index (AHI) at 12 months, sustained through five years [S1].
• The company has a global real-world patient registry (ADHERE) with 5,000 patients enrolled to collect safety, effectiveness, compliance, and satisfaction data [S1].
• Inspire sells its system directly to hospitals and ambulatory surgery centers in the U.S. and Europe, and through distributors in Japan and Singapore [S1].
• The company has 295 U.S. sales territories and 21 international territories as of December 31, 2025 [S1].
• The sales force targets ENT physicians and sleep centers, supported by direct-to-consumer marketing to drive patient awareness and demand [S1].
• U.S. reimbursement is secured through commercial insurers and Medicare, with positive coverage policies from all large national commercial payors covering over 300 million lives [S1].
• The company has a dedicated prior authorization team to assist patients and providers in obtaining reimbursement approvals [S1].
• Inspire received FDA approval for its Inspire V neurostimulator in 2024 and began marketing it in 2025 [S1].
• The company holds a comprehensive intellectual property portfolio with 119 issued U.S. patents, 83 issued foreign patents, and numerous pending applications covering its technology and future products [S1].
• Recent financial data as of September 30, 2026, shows cash and equivalents of $190.8 million, short-term investments of $137.2 million, current assets of $627.6 million, and current liabilities of $97.3 million, resulting in a current ratio of 6.45 and a cash ratio of 3.37 [S2].
• Net income for the quarter ended September 30, 2026, was a loss of $24.4 million with basic and diluted EPS of -$0.84 [S2].
• Recent news highlights include Q3 earnings and revenues surpassing expectations, new CPT codes approval for hypoglossal nerve stimulation, and ongoing efforts to raise awareness and adoption of Inspire therapy [N1][N2][N5][N6][N8].